Although it is clear that melanoma is highly dependent on transcriptional regulators for initiation and progression, the clinical use of transcriptional regulatory proteins in patients with melanoma is restricted compared with that in patients with other types of cancers, and is thus far largely restricted to HDAC inhibitors and DNMT inhibitors. Here, HDAC9 is linked to melanoma.